ENGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Given the investor's beginner level, long-term strategy, and available capital, ENGN is not a good buy at the moment. The stock is experiencing significant downward momentum, lacks positive trading signals, and has weak financial performance. While the analyst rating is positive with a high price target, the key update for the company's pivotal study is not expected until the second half of 2026, making it unsuitable for immediate investment.
The stock is in a clear downtrend with a -10.57% regular market change and additional losses in pre-market (-2.36%) and post-market (-2.76%). The MACD is negatively expanding, RSI is at 21.681 (indicating oversold conditions but no clear buy signal), and the price is approaching the S2 support level of 8.517. Moving averages are converging, showing no strong directional trend.
Jefferies initiated coverage with a Buy rating and a $28 price target, citing competitive interim data and a practice-friendly profile for detalimogene. The company's pivotal study update in 2026 could be a long-term catalyst.
Significant recent price decline (-10.57% in regular market, -2.76% post-market). Weak financial performance with no revenue growth and negative net income. No recent news or congress trading data to support sentiment.
In Q4 2025, revenue remained at $0 with no YoY growth. Net income improved to -$37.88M, up 147.60% YoY, but remains negative. EPS increased to -0.74, up 117.65% YoY. Gross margin remains at 0%. Overall, financials are weak and show no immediate signs of profitability.
Jefferies initiated coverage with a Buy rating and a $28 price target, citing competitive interim data and a differentiator in the company's practice-friendly profile. However, the key update for the pivotal study is expected in the second half of 2026, making this a long-term play rather than an immediate opportunity.
